Emcure Pharmaceuticals (EMCURE) 주식 개요
Emcure Pharmaceuticals Limited는 전 세계적으로 의약품을 개발, 제조 및 마케팅하는 회사입니다. 자세히 보기
EMCURE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Emcure Pharmaceuticals Limited 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | ₹1,891.00 |
| 52주 최고가 | ₹2,048.00 |
| 52주 최저가 | ₹1,260.00 |
| 베타 | -0.056 |
| 1개월 변동 | 1.60% |
| 3개월 변동 | 7.96% |
| 1년 변동 | 25.69% |
| 3년 변동 | n/a |
| 5년 변동 | n/a |
| IPO 이후 변동 | 39.13% |
최근 뉴스 및 업데이트
분석 기사 • Aug 09
Earnings Beat: Emcure Pharmaceuticals Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
As you might know, Emcure Pharmaceuticals Limited ( NSE:EMCURE ) just kicked off its latest first-quarter results with...
내러티브 업데이트 • Aug 07
EMCURE: Governance Shifts And Dividend Plans Will Shape Balanced Outlook
Analysts have lifted the Emcure Pharmaceuticals fair value estimate from ₹1,913.50 to ₹2,039.86, citing updated assumptions that include a slightly different discount rate, revised revenue growth expectations, a higher profit margin outlook, and a lower future P/E multiple in their price target framework. What's in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals has recommended a final dividend of ₹3.60 per equity share of ₹10 each for the financial year ending March 31, 2026, subject to shareholder approval at the AGM.Recent updates
분석 기사 • Aug 09
Earnings Beat: Emcure Pharmaceuticals Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
As you might know, Emcure Pharmaceuticals Limited ( NSE:EMCURE ) just kicked off its latest first-quarter results with...내러티브 업데이트 • Aug 07
EMCURE: Governance Shifts And Dividend Plans Will Shape Balanced Outlook
Analysts have lifted the Emcure Pharmaceuticals fair value estimate from ₹1,913.50 to ₹2,039.86, citing updated assumptions that include a slightly different discount rate, revised revenue growth expectations, a higher profit margin outlook, and a lower future P/E multiple in their price target framework. What's in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals has recommended a final dividend of ₹3.60 per equity share of ₹10 each for the financial year ending March 31, 2026, subject to shareholder approval at the AGM.내러티브 업데이트 • Jun 23
EMCURE: Capacity Expansion And Governance Resolutions Will Shape Balanced Forward Outlook
Analysts have nudged their fair value estimate for Emcure Pharmaceuticals from ₹1,891.83 to ₹1,913.50, reflecting updated assumptions around slightly higher revenue growth, a marginally adjusted profit margin, and a modestly higher future P/E multiple. What’s in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals plans to increase investments in domestic expansion, research and development, and manufacturing capacity, while also reviewing acquisition opportunities in India and international markets such as Europe and Canada.내러티브 업데이트 • Jun 06
EMCURE: Governance Actions And Expansion Investments Will Shape Steady Forward Outlook
Analysts have raised their fair value estimate for Emcure Pharmaceuticals to ₹1,891.83 from ₹1,795.67, reflecting updated assumptions around discount rates, revenue growth, profit margins and a future P/E of 31.02x. What's in the News Company executives indicate plans to increase investments in domestic expansion, research and development, and manufacturing, while also scanning for acquisition opportunities in India and internationally, including Europe and Canada (source: ET, via company commentary).분석 기사 • May 22
If EPS Growth Is Important To You, Emcure Pharmaceuticals (NSE:EMCURE) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...내러티브 업데이트 • May 03
EMCURE: Governance Meetings And Roche Partnership Will Shape Steady Forward Outlook
Analysts have maintained their price target for Emcure Pharmaceuticals at ₹1,795.67, citing unchanged assumptions around discount rate, revenue growth, profit margin and future P/E as the basis for keeping their valuation view intact. What's in the News Board meeting scheduled for May 5, 2026, to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final equity dividend, if any (company filing).내러티브 업데이트 • Apr 19
EMCURE: Upcoming Governance And Roche Agreement Will Shape Balanced Forward Outlook
Analysts have nudged their price target on Emcure Pharmaceuticals slightly higher to around ₹1,796 from about ₹1,795, citing updated assumptions for revenue growth, profit margins and a modestly lower future P/E expectation. What's in the News Emcure signed a distribution agreement with Roche for select nephrology and transplant medicines in India, covering therapies for chronic kidney disease, anemia management, and transplant care, effective April 1, 2026 (Key Developments).내러티브 업데이트 • Apr 04
EMCURE: Upcoming Governance Decisions Will Support Future Upside Potential
Analysts have kept their fair value estimate for Emcure Pharmaceuticals steady at about ₹1,794, reflecting largely unchanged assumptions around discount rate, revenue growth, profit margin and future P/E. This signals that their core view on the stock remains consistent.내러티브 업데이트 • Mar 21
EMCURE: Weight Management Franchise Will Support Future Upside Potential
Analysts have kept their price target for Emcure Pharmaceuticals steady at ₹1,794.83, citing essentially unchanged assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Emcure plans a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.내러티브 업데이트 • Mar 06
EMCURE: Weight Management Launch Will Underpin Future Shareholder Value Potential
Analysts have kept their fair value estimate for Emcure Pharmaceuticals steady at about ₹1,794.83 per share, citing unchanged assumptions for discount rate, revenue growth, profit margin and future P/E, which together support an unchanged price target narrative. What's in the News Emcure Pharmaceuticals has scheduled a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).내러티브 업데이트 • Feb 19
EMCURE: Weight Management Launch Will Support Stronger Long Term Outlook
Analysts have nudged their price target on Emcure Pharmaceuticals higher from ₹1,688.50 to about ₹1,794.83, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E, which together support a slightly richer valuation framework. What's in the News Board meeting scheduled for Feb 4, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).분석 기사 • Feb 06
Here's Why We Think Emcure Pharmaceuticals (NSE:EMCURE) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...내러티브 업데이트 • Feb 05
EMCURE: Weight Management Launch And Alliance Will Shape Balanced Outlook
Analysts have raised their fair value estimate for Emcure Pharmaceuticals from ₹1,652.50 to ₹1,688.50, reflecting updated assumptions related to revenue growth, profit margins and a slightly lower future P/E multiple. What's in the News Emcure Pharmaceuticals has scheduled a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Board Meeting).분석 기사 • Nov 14
Emcure Pharmaceuticals Limited (NSE:EMCURE) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Emcure Pharmaceuticals Limited ( NSE:EMCURE ) last week reported its latest quarterly results, which makes it a good...분석 기사 • Sep 27
These 4 Measures Indicate That Emcure Pharmaceuticals (NSE:EMCURE) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...새로운 내러티브 • Aug 10
Expansion In Chronic Therapies And Emerging Markets Will Thrive
Expansion in chronic therapies, specialty areas, and emerging markets is driving sustained revenue growth and broader international diversification.분석 기사 • May 25
Analyst Estimates: Here's What Brokers Think Of Emcure Pharmaceuticals Limited (NSE:EMCURE) After Its Yearly Report
The investors in Emcure Pharmaceuticals Limited 's ( NSE:EMCURE ) will be rubbing their hands together with glee today...분석 기사 • May 16
Emcure Pharmaceuticals Limited's (NSE:EMCURE) P/E Is On The Mark
Emcure Pharmaceuticals Limited's ( NSE:EMCURE ) price-to-earnings (or "P/E") ratio of 33.2x might make it look like a...분석 기사 • Feb 15
Emcure Pharmaceuticals Limited (NSE:EMCURE) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
The Emcure Pharmaceuticals Limited ( NSE:EMCURE ) share price has fared very poorly over the last month, falling by a...분석 기사 • Jan 06
We Think Emcure Pharmaceuticals (NSE:EMCURE) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...주주 수익률
| EMCURE | IN Pharmaceuticals | IN 시장 | |
|---|---|---|---|
| 7D | -5.9% | -1.1% | -0.7% |
| 1Y | 25.7% | 15.4% | 2.0% |
수익률 대 산업: EMCURE은 지난 1년 동안 15.4%의 수익을 기록한 Indian Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: EMCURE은 지난 1년 동안 2%를 기록한 Indian 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| EMCURE volatility | |
|---|---|
| EMCURE Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
안정적인 주가: EMCURE는 지난 3개월 동안 Indian 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: EMCURE의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1981 | 6,731 | Satish Mehta | www.emcure.com |
엠큐어 제약은 전 세계에서 의약품을 개발, 제조 및 마케팅하는 기업입니다. 부인과, 심혈관, 항감염제, HIV 항바이러스제, 호흡기, 위장, 통증 및 진통제, 혈액 관련, 종양/항종양, 항당뇨, 호르몬, 신경학/중추신경계, 피부과 등 다양한 치료 분야와 비타민, 미네랄 및 영양소 분야의 제품을 제공합니다. 또한 키랄 분자, 복합 API, 경구제, 철분 제품, 광화학 제품, 리포좀 및 동결 건조 주사제, 고효능 약물, 바이오 치료제 및 새로운 약물 전달 시스템을 포함한 다양한 플랫폼의 제품을 개발합니다.
Emcure Pharmaceuticals Limited 기초 지표 요약
| EMCURE 기초 통계 | |
|---|---|
| 시가총액 | ₹358.51b |
| 순이익 (TTM) | ₹10.11b |
| 매출 (TTM) | ₹96.83b |
35.4x
주가수익비율(P/E)3.7x
주가매출비율(P/S)EMCURE는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| EMCURE 손익계산서 (TTM) | |
|---|---|
| 매출 | ₹96.83b |
| 매출원가 | ₹39.28b |
| 총이익 | ₹57.55b |
| 기타 비용 | ₹47.44b |
| 순이익 | ₹10.11b |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 53.35 |
| 총이익률 | 59.43% |
| 순이익률 | 10.44% |
| 부채/자본 비율 | 30.6% |
EMCURE의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| Emcure Pharmaceuticals 배당 일정 | |
|---|---|
| 배당락일 | Sep 04 2026 |
| 배당 지급일 | Oct 21 2026 |
| 배당락일까지 남은 일수 | 15 days |
| 배당 지급일까지 남은 일수 | 62 days |
EMCURE는 안정적으로 배당을 지급합니까?
EMCURE 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/19 19:25 |
| 종가 | 2026/08/19 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Emcure Pharmaceuticals Limited는 11명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Kunal Randeria | Axis Capital Limited |
| null null | BOB Capital Markets Ltd. |
| Foram Parekh | BOB Capital Markets Ltd. |